To unravel the role of TCF7L2 (Transcription Factor 7 like 2) variants in type 2 diabetes mellitus

Shubhra Chowdhry; Gyanendra Kumar Sonkar; Priyanka Thapa Manger; Mohammad Mustufa Khan; Roshan Alam; Saba Khan

doi:10.51248/.v43i02.2089

Authors

Shubhra Chowdhry
Gyanendra Kumar Sonkar
Priyanka Thapa Manger
Mohammad Mustufa Khan
Roshan Alam
Saba Khan

DOI:

https://doi.org/10.51248/.v43i02.2089

Keywords:

TCF7L2, T2DM, Wnt, SNP, GLP-1

Abstract

Predisposition to diabetes is attributed to a large number of genes. TCF7L2 is one of the most significant candidate genes among them, and it is crucial for beta-cell activity and blood glucose regulation. According to previous research, TCF7L2 has been implicated in T2DM in various Indian tribes. Many studies have discovered a link between TCF7L2 gene variations and vulnerability to T2DM. These results suggest that changes in TCF7L2 expression are not only associated with insulin resistance but also with risk for genotypes connected to poor beta cell activity. TCF7L2 drives the conventional Wnt signalling pathway and functions as a nuclear ligand for beta catenin. Wnt signalling is necessary for intestinal endocrine L-cells to emit GLP-1 (glucagon-like peptide-1). As a result, a blockage in this route would cause less GLP-1 to be released, which might have an impact on the release of insulin after meals contributing to T2DM as a result. The molecular processes through which the TCF7L2 gene increases the susceptibility of T2DM will therefore be of significant interest, as will the identification of possible therapeutic targets that may be employed to treat and prevent the illness as a result of the gene variations.

Author Biographies

Shubhra Chowdhry

Department of Biochemistry, Integral Institute of Medical Sciences & Research, Integral University, Lucknow, 226026, Uttar Pradesh, India

Gyanendra Kumar Sonkar

Department of Biochemistry, King George’s Medical University, Lucknow, 226003, Uttar Pradesh, India

Priyanka Thapa Manger

Department of Biochemistry, Integral Institute of Medical Sciences & Research, Integral University, Lucknow, 226026, Uttar Pradesh, India

Mohammad Mustufa Khan

Department of Basic Medical Sciences, Integral Institute of Medical Sciences & Research, Integral University, Lucknow, 226026, Uttar Pradesh, India

Roshan Alam

Department of Biochemistry, Integral Institute of Medical Sciences & Research, Integral University, Lucknow, 226026, Uttar Pradesh, India

Saba Khan

Department of Biochemistry, Integral Institute of Medical Sciences & Research, Integral University, Lucknow, 226026, Uttar Pradesh, India

References

Jameson, J., Fauci, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L., Loscalzo, J. eds. Harrison’s principles of internal medicine. 20th ed. New York: McGraw Hill; 2018.

Wild, S., Roglic, G., Green, A., Sicree, R., King, H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27: 1047-1053.

Classification of diabetes mellitus. Geneva: World Health Organization; 2019.

Elghazawy, M.I.M.H., ElShawarby, L.A.A., Saleh, R.M.M.A, Fouad, N.T.A. TCF7L2 Polymorphism and Inflammation in Type II Diabetes: A Nutrigenetic Pilot Study. Acta Scientific Pharmaceutical Sciences. 2020; 4 (1): 02-08.

Duval, A., Busson-Leconiat, M., Berger, R., Hamelin, R. Assignment of the TCF-4 gene (TCF7L2) to human chromosome band 10q25.3. Cytogenet Cell Genet. 2000;88(3-4):264-265.

Del Bosque-Plata, L., Martinez-Martinez, E., Espinoza-Camacho, M.A., Gragnoli, C. The Role of TCF7L2 in Type 2 Diabetes. Diabetes. 2021;70(6):1220-1228.

Ip, W., Shao, W., Chiang, Y.T., Jin, T. The involvement of the wnt signalling pathway and TCF7L2 in diabetes mellitus: The current understanding, dispute, and perspective. Cell & Bioscience. 2012; 2:28

Garcia-Martínez, J.M., Chocarro-Calvo, A., Moya, C.M., Garcia-Jimenez, C. WNT/ beta -catenin increases the production of incretins by entero-endocrine cells. Diabetologia. 2009;52(9):1913-1924

Grant, S.F., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., et al., Variant of transcription factor 7 like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38(3):320-323.

Nusse, R., Varmus, H.E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome.Cell.1982; 31(1) : 99-109.

Wehrli, M., Dougan, S.T., Caldwell, K., O'Keefe, L., Schwartz, S., Vaizel-Ohayon, D., et al., Arrow encodes an LDL-receptor-related protein essential for Wingless signalling. Nature. 2000 Sep 28;407(6803):527-530.

Zhan, Tianzuo, Rindtorff, Niklas, Boutros, Michael. Wnt signaling in cancer. Oncogene.2016: 36.

Zeng, X., Tamai, K., Doble, B., Li, S., Huang, H., Habas, R. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature. 2005; 438(7069):873-877.

Wang, S., Dong, Y., Zhang, Y., Wang, X., Xu, L., Yang, S. et al., DACT2 is a functional tumor suppressor through inhibiting Wnt/ beta-catenin pathway and associated with poor survival in colon cancer. Oncogene. 2015; 34(20):2575-2585.

Roose, J., Molenaar, M., Peterson, J., Hurenkamp, J., Brantjes, H., Moerer, P. et al., The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature. 1998; 395(6702):608-612.

Brannon, M., Gomperts, M., Sumoy, L., Moon, R.T., Kimelman, D. A beta-catenin/XTcf-3 complex binds to the siamois promoter to regulate dorsal axis specification in Xenopus. Genes Dev. 1997; 11(18):2359-2370.

Chinnadurai, G. CtBP, an unconventional transcriptional corepressor in development and oncogenesis. Mol Cell. 2002; 9(2):213-224.

Cauchi, S., Meyre, D., Dina, C., Choquet, H., Samson, C., Gallina, S., et al., Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes. 2006;55(10):2903-2908

Kaminska, D., Kuulasmaa, T., Venesmaa, S., Käkelä, P., Vaittinen, M., Pulkkinen, L. Adipose tissue TCF7L2 splicing is regulated by weight loss and associates with glucose and fatty acid metabolism. Diabetes. 2012; 61(11):2807-2813.

Liu, Z., Habener, J.F. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem. 2008; 283:8723-8735.

Groves, C.J., Zeggini, E., Minton, J., Frayling, T.M., Weedon, M.N., Rayner, N.W., et al., Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes.2006;55(9): 2640-2644.

Wang, J., Zhang, J., Li, L., Wang, Y., Wang, Q., Zhai, Y. et al., Association of rs12255372 in the TCF7L2 gene with type 2 diabetes mellitus: a metaanalysis. Braz J Med Biol Res. 2013;46(4):382-393.

Li, Tian, T, Jin. The incretin hormone GLP-1 and mechanisms underlying its secretion. Journal of Diabetes. 2016; 8: 753-765.

Prokunina-Olsson, L., Welch, C., Hansson, O., Adhikari, N., Scott, L.J., Usher, N. et al., Tissue specific alternative splicing of TCF7L2. Hum Mol Genet. 2009; 18(20):3795-3804.

Muller, T.D., Finan, B., Bloom, S.R., D'Alessio, D., Drucker, D.J., Flatt, P.R. et al., Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019; 30:72-130.

Drucker, D.J., Habener, J.F., Holst, J.J. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017;127(12):4217-4227.

Yabe, D., Seino, S. Two incretin hormones GLP-1 and GIP: comparison of their actions on insulin secretion and beta cell preservation. Prog Biophys Mol Biol. 2011; 107:248-256.

Graaf, Cd., Donnelly, D., Wootten, D., Lau, J., Sexton, P.M., Miller, L.J. et al., Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacol Rev. 2016; 68(4):954-1013.

Leech, C.A., Chepurny, O.G., Holz, G.G. Epac2-dependent Rap1 activation and the control of islet insulin secretion by glucagon-like peptide-1. Vitam Horm. 2010; 84:279-302.

Dalle, S., Quoyer, J., Varin, E., Costes, S. Roles and regulation of the transcription factor CREB in pancreatic beta -cells. Curr Mol Pharmacol. 2011; 4:187-195.

Donnelly, D. The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol. 2012;166(1):27-41.